The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age
2020 · Biomarker Research · 41 citations
https://doi.org/10.1186/s40364-020-00188-2
Y
Yiqing Wang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
92
Papers
1.1K
Citations
19
h-index
29
i10-index
Yiqing Wang is an academic researcher from Southern Methodist University. The author has contributed to research in topics: Cancer-related gene regulation & RNA modifications and cancer & Cancer Immunotherapy and Biomarkers. The author has an h-index of 19, co-authored 79 publications.
ORCID: 0000-0003-3994-6517Papers by this author
worksDulaglutide, a long-acting GLP-1 receptor agonist, can improve hyperandrogenemia and ovarian function in DHEA-induced PCOS rats
2021 · Peptides · 40 citations
https://doi.org/10.1016/j.peptides.2021.170624
Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors
2022 · Cancer Immunology Immunotherapy · 30 citations
https://doi.org/10.1007/s00262-022-03151-2
Novel insights into the consequences of obesity: a phenotype-wide Mendelian randomization study
2022 · European Journal of Human Genetics · 24 citations
https://doi.org/10.1038/s41431-021-00978-8
Integrative systems biology framework discovers common gene regulatory signatures in mechanistically distinct inflammatory skin diseases
2025 · npj Systems Biology and Applications · 6 citations
https://doi.org/10.1038/s41540-025-00498-x
The Emerging Roles of Extracellular Vesicles in Ovarian Cancer
2020 · Current Drug Metabolism · 3 citations
https://doi.org/10.2174/1389200221666201110155721
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat